The global cancer biomarkers market has experienced substantial growth over the last couple of years.
This market is expected to grow at a CAGR of 11.6% from 2015 to 2020. Factors such as rising incidence of cancer; technological advancements in omics technologies; favorable government funding for cancer research; increased demand for personalized medicines in cancer therapies; and increased use of biomarkers in drug discovery development and clinical trials are expected to fuel the growth of the cancer biomarkers market during the forecast period.
However, poorly suited regulatory and reimbursement systems of biomarker tests, high capital investments for biomarker discovery and development, and sample collection and storage difficulties are restraining the growth of this market.
The global cancer biomarkers market is segmented on the basis of type of biomarkers, tumor type, profiling technologies, applications, and geography. Based on type, the market is segmented into protein biomarkers, genetic biomarkers, and others which include viral, cell, and carbohydrate biomarkers. Based on tumor type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other type of cancers such as Gastrointestinal Stromal Tumors (GIST), lung, ovarian, bladder, pancreatic, kidney, melanoma, and leukemia.
Based on profiling technologies, the market is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics. Based on applications, the market is segmented into diagnostics, drug discovery and development, prognostics, risk assessment, and others which include surrogate endpoints, recurrence, personalized medicine, and therapeutics.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America and Middle East and Africa).
The Asia-Pacific market is poised to register the highest growth rate in the forecast period owing to the favorable government funding for cancer biomarker research, rising prevalence of cancer, increasing demand for advanced healthcare facilities in developing economies such as India and China, increasing number of clinical trials, and increasing focus of international players in emerging markets. The global cancer biomarkers market is consolidated in nature at the top. In order to maintain their market shares, leading players are continuously focusing on new product developments and upgrading their existing products to enhance their product portfolios. Increasing competition among major players is expected to drive innovation in the market, thereby helping the industry to overcome existing challenges in various applications such as diagnostics, drug discovery and development, personalized medicine, among others.
Major players in this market are:
Abbott Laboratories (U.S.)
Affymetrix Inc. (U.S.)
Roche Diagnostics Ltd. (Switzerland)
Illumina, Inc. (U.S.)
Qiagen NV (Netherlands)
Agilent Technologies (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Merck & Co. Inc. (U.S.)
Becton Dickinson and Company (U.S.)
Hologic Inc. (U.S.).
Cancer biomarkers are molecules secreted by a tumor or a specific response of the body to the presence of cancer.
These are substances or processes that are indicative of the presence of cancers in the human body, and enhance the cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics tools.
The identification of cancer biomarkers is important to detect the tumors in the body.
These are used for diagnostics, drug discovery and development, prognostics, personalized medicine, and surrogate endpoints and are becoming an integral part of various industries such as pharmaceutical and clinical trial companies, due to their ability to reduce the time and cost of the drug discovery and development process and clinical trials.
Global Cancer Biomarkers Market, by Type
Global Cancer Biomarkers Market, by Tumor Type
- Protein Biomarkers
- Genetic Biomarkers
- Others (Cell, Viral, and Carbohydrate Biomarkers)
Global Cancer Biomarkers Market, by Profiling Technologies
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Others (Gastrointestinal stromal tumors (GIST), Lung, Ovarian, bladder, Pancreatic, Kidney, Melanoma, and Leukemia)
Global Cancer Biomarkers Market, by Applications
- Omics Technologies
- Mass Spectrometry
- 2D Gel Electrophoresis
- Protein Microarray Technology
- Antibody Array Technology
- Peptide Array Technology
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Other Omics Technologies (Metabolomics and Glycomics)
- Imaging Technologies
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Computed Tomography
- Immunohistochemistry(IHC) Tests
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Cytogenetics based tests
- In situ Hybridization
- Others (Karyotyping, AmpliChip and In Vitro Diagnostic Multivariate Index Assays (IVDMIA))
Global Cancer Biomarkers Market, by Region
- Drug Discovery and Development
- Risk Assessment
- Others (Personalized Medicine, Surrogate endpoints, Recurrence, and Therapeutics)
Tweets From The Industry
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Rest of the World (RoW)
- Latin America
- Middle East and Africa
Please find more about Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020 at reports.zursh.com
Click on below items to see free updates about the topic covered.
Click on below items to see free resources and reports about the topic covered.